New combo aims to rev up immune system against lung cancer

NCT ID NCT05493566

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding low-dose interleukin-2 (IL-2) to the immunotherapy drug pembrolizumab (Keytruda) can better activate the immune system against stage IV non-small cell lung cancer. The study will enroll 15 people who have not had prior treatment for their advanced cancer. Researchers will measure changes in immune cells and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Low-dose interleukin-2 (IL-2) plus pembrolizumab (Keytruda)
What this could lead to: If it works, this could point toward a more effective immune-based treatment for advanced lung cancer.
What could go wrong: This is a very early (Phase 1) trial with only 15 people. It is designed mainly to check immune response, not yet to prove the treatment works. Side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8 STAGE IVA LUNG CANCER AJCC V8 STAGE IVB LUNG CANCER AJCC V8

Contacts and locations

Locations

Emory University/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.